Focused ultrasound thalamotomy in Parkinson’s Disease

UVA’s Scott Sperling and Jeff Elias, who already used focused ultrasound to treat essential tremor, have just published the results of  a small study showing the efficacy of the technology in Parkinson’s Disease.

The sound waves were shown to interrupt brain circuits responsible for the uncontrollable shaking associated with the disease. The researchers claim that their study also offers “comprehensive evidence of safety” in its effect on mood, behavior and cognitive ability, which has not previously been studied.

According to Sperling, “In this study, we extended these initial results and showed that focused ultrasound thalamotomy is not only safe from a cognitive and mood perspective, but that patients who underwent surgery realized significant and sustained benefits in terms of functional disability and overall quality of life.”

27 adults with severe Parkinson’s tremor that had not responded to previous treatment were divided  into two groups. Twenty received the procedure, and a control group of seven (who were later offered the procedure) did not. Participants reported improved quality of life, including their ability to perform simple daily tasks, emotional wellbeing, and a lessened sense of stigma due to their tremor, at both three and twelve months.

The team found that mood and cognition, and the ability to go about daily life, ultimately had more effect on participants’ assessment of their overall quality of life than did remor severity or the amount of tremor improvement.

Cognitive decline was seen in some participants after the study, in that they were less able to name colors and think of and speak words. The cause of this was unclear, and must be investigated. The researchers suggested this could be a result of the natural progression of Parkinson’s.


Join ApplySci at the 10th Wearable Tech + Digital Health + Neurotech Silicon Valley conference on February 21-22 at Stanford University — Featuring:  Zhenan BaoChristof KochVinod KhoslaWalter Greenleaf – Nathan IntratorJohn MattisonDavid EaglemanUnity Stoakes Shahin Farshchi Emmanuel Mignot Michael Snyder Joe Wang – Josh Duyan – Aviad Hai Anne Andrews Tan Le

Implanted sensors track dopamine for a year

Helen Schwerdt, Ann Graybiel, Michael Cima, Bob Langer, and MIT colleagues have developed and implantable sensor that can measure dopamine in the brain of rodents for more than one year.  They believe that this can inform the treatment and understanding of Parkinson’s and other brain diseases.

According to Graybiel, “Despite all that is known about dopamine as a crucial signaling molecule in the brain, implicated in neurologic and neuropsychiatric conditions as well as our abilty to learn, it has been impossible to monitor changes in the online release of dopamine over time periods long enough to relate these to clinical conditions.”

The sensors arenearly invisible to the immune system, avoiding scar tissue that would impede accuracy. After  implantation, populations of microglia  and astrocytes were the same as those in brain tissue that did not have the probes.

In a recent animal  study, three to five sensors per were implanted 5 millimeters deep in the striatum. Readings were taken every few weeks, after dopamine release was stimulated in the brainstem, traveling to the striatum. Measurements remained consistent for up to 393 days.

If developed for use in humans, these sensors could be useful for monitoring Parkinson’s patients who receive deep brain stimulation.


Join ApplySci at the 9th Wearable Tech + Digital Health + Neurotech Boston conference on September 24, 2018 at the MIT Media Lab.  Speakers include:  Rudy Tanzi – Mary Lou Jepsen – George ChurchRoz PicardNathan IntratorKeith JohnsonJohn MattisonRoozbeh GhaffariPoppy Crum – Phillip Alvelda Marom Bikson – Ed Simcox – Sean Lane